Western Blot Immunostaining

After separated proteins are transferred to the blotting membrane, the membrane will be “blocked” and then incubated with antigen-specific antibodies, a process known as immunostaining. Blocking is an essential pretreatment that coats the membrane with inert proteins, as the membrane has indiscriminately high affinity for all proteins. This step minimizes non-specific antibody binding, thereby reducing background noise and ensuring that antibodies only interact with their intended targets. The subsequent immunostaining relies on the high specificity of primary and secondary antibodies to bind the protein of interest and produce a detectable signal that is proportional to the target protein's abundance. A key consideration in this process is the careful selection of the right antibody combination, as the primary and secondary antibodies must be well-matched to the target protein and detection system. Optimizing reagents, such as blocking buffers, antibody dilutions, and wash solutions, will also play a central role in achieving consistent, high-quality data. Detection methods range from traditional chemiluminescence to fluorescent labels for multiplexed imaging, making the choice of antibody conjugate a key experimental consideration.

Created in BioRender. Estipona, D. (2026) https://BioRender.com/ldcym0r

The general Western blot immunostaining protocol follows a sequential series of blocking, antibody incubations, and thorough washing steps. An example protocol is outlined as follows: 

1. Block the membrane at room temperature with gentle shaking in a blocking buffer, often formulated with non-fat dry milk or bovine serum albumin (BSA) in TBST or PBST. This prevents non-specific binding of antibodies to the membrane. Blocking can take up to one hour, but commercial blocking buffers can shorten the process.

2. Dilute the primary antibody in blocking solution or a specialized antibody dilution buffer according to the manufacturer's specifications. A more optimal concentration may also be determined, depending on the protein abundance in the sample. 

3. Incubate the membrane in the diluted primary antibody. Depending on the nature of the proteins in the sample, this can be done at room temperature for 1 to 2.5 hours or overnight at 4°C.

4. Wash the membrane three to four times in wash buffer to remove unbound antibodies. This is typically done at 5 to 10 minutes each at room temperature with shaking.

5. If using a conjugated secondary antibody, dilute the secondary antibody in blocking solution or a specialized antibody dilution buffer according to manufacturer specifications. It is also recommended to titrate for the most optimal concentrations alongside the primary antibody. 

6. Incubate the membrane in the diluted secondary antibody at room temperature for 1 hour with gentle shaking.

7. Wash the membrane again, three to four times for 5 to 10 minutes each in wash buffer.

8. Prepare and apply the detection reagent according to the manufacturer's recommendations. Substrates will need to be added for antibodies conjugated to HRP and AP, while fluorescently labeled antibodies generally can be detected directly.

9. (Optional) If using chemiluminescent detection and the experiment calls for detecting multiple proteins from a single blot, the membrane may be stripped of presently bound antibodies and re-probed with new antibodies. This involves incubating the membrane with a stripping buffer, then repeating the antibody incubation with a new antibody set. Note that high-affinity antibodies may be more challenging to unbind, requiring harsher stripping conditions. 

A preparative blocking step is necessary to prevent the non-specific binding of detection antibodies to the blotting membrane before immunostaining. Here, a blocking buffer is applied to the membrane, coating it with inert proteins and ensuring that detection antibodies will bind only with the intended target antigens. The result is a significant reduction of background noise as well as false positives. Ineffective blocking, which can stem from insufficient application or an ineffective blocking agent, can lead to off-target binding and unclear results during data analysis. In this part of the Western blot workflow, blocking should be properly optimized to ensure meaningful blotting results. 

Formulating a blocking buffer appropriate to the sample is an important preparatory step. A widely used blocking agent is milk, which provides a concentrated source of casein and whey. In the context of Western blotting, the reagent generally comes in the form of non-fat dry milk or skim milk powder, and is favored for being inexpensive and widely available. However, being that milk-derived casein is a phosphoprotein, using anti-phospho antibodies can lead to high background signals when using milk in the blocking buffer. Biotin can also be found in milk, which can interfere when using a biotin-avidin detection system.

Another common blocker is BSA, which is an ideal alternative to milk, particularly for the reasons mentioned above. For example, a BSA-based blocking buffer formulation has been reported to be effective for antibody binding against phospho-amino acids, which contains the following components: 5% BSA, 5% Amicase® (a mixture of free amino acids and hydrolyzed peptides), and a 5% membrane-blocking agent (MBA). Other less commonly used blocking agents include fish gelatin, polyvinylpyrrolidone-40 (PVP-40), and soymilk. Finally, commercial blocking buffers, which typically use proprietary formulations, come in wide, diverse varieties and are worth exploring, especially when milk or BSA exhibits suboptimal blocking.

The appearance of multiple non-specific bands can indicate inadequate blocking for the specific antibody detection system. To troubleshoot this, users may consider several changes to the protocol, such as increasing the blocking duration, increasing the concentration of the blocking agent, including another blocking agent, or changing the blocking formulation entirely.

Selecting a reliable primary antibody is the first step to generating meaningful Western blot results. For an antibody to perform well, it must effectively recognize and bind its target epitope (specificity) while distinguishing that target from the complex mixture of proteins present in the sample (selectivity). Key factors to evaluate during primary antibody selection include clonality, target protein abundance, and species cross-reactivity.

Clonality is a particularly important consideration when working with difficult-to-detect antigens. Monoclonal antibodies offer high specificity for a single epitope, which lends itself to greater reproducibility across experiments. Polyclonal antibodies, by contrast, recognize multiple epitopes on a given protein, which can be advantageous when detecting low-abundance targets or protein variants carrying point mutations that might otherwise abolish monoclonal binding.

The nature of the target epitope itself warrants careful attention. Because Western blotting involves SDS-denaturation and heat treatment, antibodies raised against linear epitopes are generally better suited for this application than those targeting conformational epitopes, which depend on the native three-dimensional structure of the protein. It is also worth determining whether the target epitope is shared among protein isoforms or proteolytic degradation products, as cross-reactivity with these other antigens can give rise to additional bands that can complicate interpretation.

In Western blotting, immunostaining most commonly follows an indirect format, pairing an unlabeled primary antibody with a labeled secondary antibody for antigen detection. Multiple secondary antibodies can bind a single primary antibody, resulting in signal amplification that is particularly advantageous for detecting low-abundance targets. Selecting a secondary antibody that is well-matched to the primary is essential. Among the initial considerations, the secondary antibody's target specificity must match the host species and isotype (such as IgG1 or IgG2a) of the primary antibody.

The detection chemistry of the labeled secondary antibody is another important consideration. Horseradish peroxidase (HRP)-conjugated secondaries, most often paired with enhanced chemiluminescence (ECL) detection, are widely used in Western blotting for their high sensitivity. However, chemiluminescence is inherently subject to variability, as the signal depends on substrate-enzyme kinetics that can shift over time and across the surface of the blot. In regions of high HRP concentration (such as those corresponding to abundant targets), the substrate can be rapidly exhausted, leading to "ghost" bands or reverse banding. This non-linearity and narrow dynamic range can be partially mitigated by titrating protein load and primary antibody concentration.

Fluorophore-labeled antibodies offer an alternative method of detection that serves quantitative and multiplexing applications. Fluorophores generate stable, reproducible signals that, unlike chemiluminescence, are unaffected by timing and local substrate availability. Multiplexed detection of several protein targets on a single blot is achievable by using spectrally distinct fluorophores, eliminating the need to strip and re-probe the membrane. Fluorescence-based detection is broadly recognized as a reliable method for quantitative Western blotting and is supported by a wide range of fluorescence-enabled imaging platforms.

Secondary antibodies should be titrated in conjunction with primary antibodies to determine optimal working concentrations, with the goal of maximizing signal-to-noise ratio and ensuring detection remains within a linear dynamic range. Including "no primary antibody" controls is good practice for distinguishing specific target signal from non-specific secondary antibody binding to the membrane. When publishing findings, secondary antibody details (including name, source, lot number, and working concentration) should be reported in full, as these are frequently and unfortunately omitted from the methods sections of scientific publications.

Taylor SC, Rosselli-Murai LK, Crobeddu B, Plante I. A critical path to producing high quality, reproducible data from quantitative western blot experiments. Sci Rep. 2022;12:17532. doi:10.1038/s41598-022-22294-x.

Pillai-Kastoori L, Schutz-Geschwender AR, Harford JA. A systematic approach to quantitative Western blot analysis. Anal Biochem. 2020;593:113608. doi:10.1016/j.ab.2020.113608.

Bass JJ, Wilkinson DJ, Rankin D, et al. An overview of technical considerations for Western blotting applications to physiological research. Scand J Med Sci Sports. 2017;27(1):4-25. doi:10.1111/sms.12702.

Ha SG, Park JH, Kim MY, Lee SJV. Brief guide to western blot assays. Molecules and Cells. 2025;100297. doi:10.1016/j.mocell.2025.100297.

Mishra M, Tiwari S, Gomes AV. Protein purification and analysis: next generation western blotting techniques. Expert Rev Proteomics. 2017;14(11):1037-1053. doi:10.1080/14789450.2017.1388167.

Liu D, Wu H, Cui S, Zhao Q. Comprehensive Optimization of Western Blotting. Gels. 2023;9:652. doi:10.3390/gels9080652.
Brooks HL, de Castro Brás LE, Brunt KR, et al. Guidelines on antibody use in physiology research. Am J Physiol Renal Physiol. 2024;326:F511-F533. doi:10.1152/ajprenal.00347.2023.

Mason E. How to improve western blot reproducibility. Biocompare. July 18, 2023. Accessed March 2026. https://www.biocompare.com/Editorial-Articles/597371-How-to-Improve-Western-Blot-Reproducibility/

Perkins MV, Sachetto ATA, Mackman N. Optimization of a Western blot protocol for the detection of low levels of tissue factor in human cells. Res Pract Thromb Haemost. 2025;103016. doi:10.1016/j.rpth.2025.103016.

Sormunen A, Koivulehto E, Alitalo K, et al. Comparison of automated and traditional western blotting methods. Methods Protoc. 2023;6:43. doi:10.3390/mps6020043.
Li C, Guan J, Li Y, et al. Protocol for high-sensitivity western blot on murine hematopoietic stem cells. STAR Protoc. 2023;4:102578. doi:10.1016/j.xpro.2023.102578.

DeNies MS, Liu AP, Schnell S. Seeing beyond the blot: A critical look at assumptions and raw data interpretation in Western blotting. Biomolecular Concepts. 2024;15:20220047. doi:10.1515/bmc-2022-0047.

Kroon C, Breuer L, Jones L, et al. Blind spots on western blots: Assessment of common problems in western blot figures and methods reporting with recommendations to improve them. PLoS Biol. 2022;20(9):e3001783. doi:10.1371/journal.pbio.3001783.

Sule R, Rivera G, Gomes AV. Western blotting (immunoblotting): history, theory, uses, protocol, and problems. Biotechniques. 2023;75(3):99-114. doi:10.2144/btn-2022-0034.

Tanabe L. The ultimate quick tips & tricks guide to western blots. Biocompare. May 09, 2024. Accessed March 2026. https://www.biocompare.com/Editorial-Articles/613149-The-Ultimate-Quick-Tips-Tricks-Guide-to-Western-Blots/